Last $13.94 USD
Change Today +0.23 / 1.68%
Volume 32.7K
ITCI On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 2:14 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

intra-cellular therapies inc (ITCI) Snapshot

Open
$13.75
Previous Close
$13.71
Day High
$14.23
Day Low
$13.52
52 Week High
03/13/14 - $21.26
52 Week Low
12/27/13 - $10.00
Market Cap
409.7M
Average Volume 10 Days
47.7K
EPS TTM
$-1.10
Shares Outstanding
29.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTRA-CELLULAR THERAPIES INC (ITCI)

Related News

No related news articles were found.

intra-cellular therapies inc (ITCI) Related Businessweek News

No Related Businessweek News Found

intra-cellular therapies inc (ITCI) Details

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS). Its lead product candidate, ITI-007, which is in clinical development for the treatment of exacerbated and residual schizophrenia; bipolar disorders; sleep deficits associated with neurologic and psychiatric disorders; behavioral disturbances associated with dementia, including Alzheimer’s disease; sleep maintenance insomnia; major depressive disorders; and autism spectrum disorders, posttraumatic stress disorder, and intermittent explosive disorder. The company also develops ITI-002 phosphodiesterase (PDE) 1 inhibitors, including ITI-214 program that is in Phase-I clinical trial for the treatment of cognitive dysfunction in schizophrenia, Parkinson’s disease, cognitive impairment in Alzheimer’s disease, and attention deficit/hyperactivity disorders; as well as for cardiovascular and other diseases. In addition, it develops early stage drug development programs comprising ITI-012 casein kinase 1 inhibitors and ITI-009 gamma secretase activating protein inhibitors for Alzheimer’s disease. Further, the company develops PDE2 and PDE9 targets for treating neurodegeneration and bioenergetic failure in various CNS diseases. It has a license and collaboration agreement with Takeda Pharmaceutical Company Limited to research, develop, and commercialize the company’s proprietary compound ITI-214 and other selected compounds that selectively inhibit PDE1 for use in the prevention and treatment of human diseases. The company is headquartered in New York, New York.

intra-cellular therapies inc (ITCI) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $1.1M
Co-founder and Vice President of Business Dev...
Total Annual Compensation: $283.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $357.5K
Compensation as of Fiscal Year 2013.

intra-cellular therapies inc (ITCI) Key Developments

Intra-Cellular Therapies, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Intra-Cellular Therapies, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenues of $219,238 against $643,264 a year ago. Loss from operations was $4,611,584 against $8,048,043 a year ago. Net loss was $4,533,539 or $0.15 per share basic and diluted against $8,277,391 or $0.56 per share a year ago. For the six months, the company reported revenues of $387,025 against $1,241,516 a year ago. Loss from operations was $9,186,047 against $13,448,659 a year ago. Net loss was $9,076,823 or $0.33 per share basic and diluted against $13,915,768 or $0.95 per share a year ago.

Intra-Cellular Therapies, Inc., Q2 2014 Earnings Call, Aug 12, 2014

Intra-Cellular Therapies, Inc., Q2 2014 Earnings Call, Aug 12, 2014

Intra-Cellular Therapies, Inc. Appoints Michael Halstead as Senior Vice President and General Counsel

Intra-Cellular Therapies, Inc. announced the appointment of Michael Halstead as Senior Vice President and General Counsel. In this role, Mr. Halstead will manage the legal affairs of the company, and will report directly to Sharon Mates, Ph.D., CEO and Chairman of Intra-Cellular Therapies. Mr. Halstead most recently served as Senior Vice President, Corporate Development at Warner Chilcott plc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ITCI:US $13.94 USD +0.23

ITCI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ITCI.
View Industry Companies
 

Industry Analysis

ITCI

Industry Average

Valuation ITCI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 213.2x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 139.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTRA-CELLULAR THERAPIES INC, please visit www.intracellulartherapies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.